About ORI

News & Events

Research Misconduct

RCR Resources

Programs

Policies & Regulations

Assurance Program

Publications - Benjamin Djulbegovic

Printer FriendlyPrinter Friendly

Articles

Djulbegovic B, Kumar A, Soares HP, Hozo I, Bepler G, Clarke M, Bennett CL. “New Cancer Treatment Successes Identified in Phase 3 Randomized Controlled Trials Conducted by the National Cancer Institute-Sponsored Cooperative Oncology Groups, 1955 to 2006.” Archives of Internal Medicine 2008, 168(6): 632-642.

Djulbegovic B. "Articulating and Responding to Uncertainties in Clinical Research." Journal of Medical Philosophy 2007, 32:79-98.

Djulbegovic, B, Cantor A, Clarke M. "The Importance of Preservation of the Ethical Principle of Equipoise in the Design of Clinical Trials: Relative Impact of the Methodological Quality Domains on the Treatment Effect in Randomized Controlled Trials." Accountability in Research  2003, 10 (4):301-315.

Kumar A, Soares HP, BalducciL, Djulbegovic B. "Treatment Tolerance and Efficacy in Geriatric Oncology: A Systematic Review of Phase III Randomized Trials Conducted by 5 NCI-Sponsored Cooperative Trials."  Journal of Clinical Oncology 2007, 25: 1272-1276.


Kumar A, Soares H, Wells R, Clarke M, Hozo I, Bleyer A, Reaman G, Chalmers I,  Djulbegovic, B. "Are Experimental Treatments for Cancer in Children Superior to Established Treatments?  Observational Study of Randomised Controlled Trials by the Children's Oncology Group."  British Medical Journal 2005, 331: 1295-1298.

Soares, HP, Daniels S, Kumar A, Clarke M, Scott C, Swann S, Djulbegovic B.  "Bad Reporting Does Not Mean Bad Methods for Randomised Trials: Observational Study of Randomised Controlled Trials Performed by the Radiation Therapy Oncology Group." British Medical Journal  2004, 328 (7430):22-24.


Letters to Editors

Djulbegovic B. 2004 "Well Informed Uncertainties About the Effects of Treatment: Paradox Exists in Dealing with Uncertainty." British Medical Journal. 2004, 328 (7446): 1018.

Abstracts

Djulbegovic B, Kumar A, Soares HP.  "What Is the Probability That New Cancer Treatments Are Better Than Standard Treatments?" Proceedings of the American Society of Clinical Oncology 2006, 24 (18S): 330s.


Djulbegovic B, Kumar A, Soares H, et al. "A Relationship Between Ethics of Clinical trials and Therapeutic Advances in Cancer." Proceedings of the American Society for Clinical Oncology 2005, 550.

Djulbegovic B, Soares HP, Kumar A. "Citation Impact of Breakthrough Intervensions for Malignant Blood Disorders."  Blood 2005, 106:871a.

Djulbegovic B, Soares H, Daniels S, Kumar A, Clark M. "Evaluation of New Treatments in Cancer: Are They Better Than Standard Treatments?" 11th Cochrane Colloquium, 2003, 14.

Kumar A, Soares H, Djulbegovic B. "Possible Misleading Conclusions Due to Inappropriate Approach in Dealing with Data Extraction from Factorial Design Randomized Trials.  14th Cochrane Colloquium, 2006.

Kumar A, Soares H, Djulbegovic B.  "Are Statistically Non-Significant Findings Necessarily Negative?  A Review of All Phase III Randomized Controlled Trials Conducted by NCI Cooperative Groups." Blood 2005, 106:89a.

 

Kumar A, Soares H, Serdarevic F, Hozo I, Buckener J, Wells RJ, Fiorica J, Swann S, Sargent D, Djulbegovic B. "How Many New Treatments Are "Breakthroughs"? Evaluation of Innovations in Cancer." Proceedings of the American Society for Clinical Oncology 2005, 544s.

Kumar A, Soares H, Djulbegovic B. "High Proportion of High Quality Trials Conducted by the NCI Are Negative or Inconclusive. 13th Cochrane Colloquium, 2005.

Kumar A, Soares HP, Wells RJ, Khayat A, Clarke M, Hills RK, Bleyer A, Reaman G, Djulbegovic B. "Experimental Vs. Control Interventions in Cancer: Which Is Better? The Children's Oncology Group Experience." Proceedings of the American Society for Clinical Oncology 2004, 521.

Soares HP, Djulbegivic B, Kumar A, Tanvetyanon T, Bepler G.  "Evaluation of Publicly-Sponsored Lung Cancer Trials in US: Are Experimental Treatments Better Than the Control Ones?" Proceedings of the American Society of Clinical Oncology 2006, 24 (18S):403s.

Soares HP, Kumar A. Djulbegovic B. "Quality of Reporting of Harms in the NCI Sponsored Phase III Hematological Malignancies Trials."  Blood 2005, 106:89a.

Soares H, Kumar A. Clarke M, Djulbegovic  B.  "How Long Does It Take to Publish a High Quality Trial in Oncology." 13th Cochrane Colloquium, 2005.

Soares H, Kumar A, Serdarevic F, Fiorica J, Wells RJ, Swann S, Buckener J, Sargent D, Hozo I, Djulbegovic B. Equipoise Principle and NCI-Sponsored Clinical trials: Are Investigators Truly Uncertain about Their Comparisons? Proceedings of the American Society for Clinical Oncology 2005, 540.

Soares H, Kumar A, Serdarevic F, Cantor A, Clarke M, Hozo I, Djulbegovic B. Findings of Clinical Research Cannot be Predicted in Advance: An Empirical Study of Cancer Trials. 12th Cochrane Colloquium 2004, 95.

Soares, HP, Kumar A, Daniels S, Sargent DJ, Buckener JC, Swann S, Smith RE, Khyat A, Wells RJ, Djulbegovic B.  "Lack of Publication Bias in Randomized Clinical Trials Sponsored by the National Cancer Institute and Performed by Cooperative Oncology Groups."  Proceedings of the American Society for Clinical Oncology  2004, 25:518.

Soares HP, Yang X, Clark OA, Kumar A, Djulbegovic B. "How Early Could We Have Known That Some Hematological Interventions Were Effective?  Blood 2003, 102:497a.

Review Articles

Soares HP, Kumar A, Daniels S, Swann S, Cantor A, Hozo I, Clark M, Serdarevic F, Gwede C, Trotti A, Djulbegovic B. "Evaluation of New Treatments in Radiation Oncology: Are They Better than Standard Treatments."

Journal of the American Medical Association

  2005, 293 (8):970-978.